Related Experiment Video
Updated: Jul 3, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
In vitro activity of WY-49605, a penem antimicrobial
G M Eliopoulos1, C B Wennersten, G Cole
1Department of Medicine, Deaconess Hospital One Deaconess Road, Boston, MA 02215, USA.
Abstract:
The in vitro activity of the penem antimicrobial WY-49605 was compared with those of other agents available for oral administration. Based on concentrations inhibiting 90% of isolates (MIC(90)s), the penem inhibited methicillin-susceptible staphylococci (MIC(90) = 0.25 microg/ml), penicillin-susceptible streptococci (MIC(90) < or = 0.12 microg/ml) and several other Gram-positive genera at concentrations comparable or superior to the most active comparison agents. WY-49605 and cefpodoxime were the most active agents against members of the family Enterobacteriaceae. Most strains of Enterococcus faecalis and Bacteroides fragilis were susceptible to the new agent at concentrations < or =4microg/ml, while Pseudomonas aeruginosa, Enterococcus faecium, and methicillin-resistant Staphylococcus aureus were resistant to all agents tested.
Insights
The novel penem antimicrobial WY-49605 shows strong in vitro activity against many Gram-positive bacteria, including methicillin-susceptible staphylococci and penicillin-susceptible streptococci. It is also effective against Enterobacteriaceae, Enterococcus faecalis, and Bacteroides fragilis.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- The emergence of antibiotic resistance necessitates the development of new antimicrobial agents.
- Oral antimicrobial agents are crucial for treating a wide range of bacterial infections.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of the novel penem WY-49605.
- To compare its activity with existing oral antimicrobial agents against various clinically relevant bacteria.
Main Methods:
- Minimum inhibitory concentrations (MICs) were determined for WY-49605 and comparator agents against a panel of bacterial isolates.
- MIC(90) values (concentrations inhibiting 90% of isolates) were calculated and compared.
Main Results:
- WY-49605 demonstrated potent activity against methicillin-susceptible Staphylococcus (MIC(90) = 0.25 microg/ml) and penicillin-susceptible Streptococcus (MIC(90) <= 0.12 microg/ml).
- It exhibited comparable or superior activity against other Gram-positive genera versus existing agents.
- WY-49605 and cefpodoxime were the most active agents against Enterobacteriaceae.
- Susceptibility was observed for Enterococcus faecalis and Bacteroides fragilis (MIC <= 4 microg/ml).
- Pseudomonas aeruginosa, Enterococcus faecium, and methicillin-resistant Staphylococcus aureus showed resistance to all tested agents.
Conclusions:
- WY-49605 is a promising oral penem antimicrobial with broad-spectrum activity against key Gram-positive pathogens and Enterobacteriaceae.
- Its in vitro profile suggests potential utility in treating infections caused by susceptible bacteria, though resistance was noted in certain strains.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Antimicrobial Effectiveness
Production of Antibiotics

